Hepatitis Delta Virus Kinetics under the Prenylation Inhibitor Lonafarnib Suggest HDV-Mediated Suppression of HBV Replication von Yurdaydin, C, Borochov, N, Kalkan, C, DebRoy, S, Karatayli, E, Haynes-Williams, V, Karatayli, S.C, Canini, L, Uprichard, S.L, Bozdayi, A. Mihat, Choong, I, Cory, D, Heller, T, Cotler, S, Idilman, R, Glenn, J.S, Dahari, H

Volltext

A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study von Yurdaydin, C, Idilman, R, Keskin, O, Kalkan, C, Karakaya, M.F, Caliskan, A, Yurdcu, E, Karatayli, S.C, Bozdayi, M, Koh, C, Heller, T, Glenn, J

Volltext

The prenylation inhibitor lonafarnib can induce post-treatment viral clearance in patients with chronic delta hepatitis resulting in alt normalization and regression of fibrosis von Yurdaydin, C, Idilman, R, Kalkan, C, Karakaya, M.F, Caliskan, A, Keskin, O, Yurdcu, E, Karatayli, S.C, Bozdayi, M, Koh, C, Heller, T, Glenn, J

Volltext

43 INTERLEUKIN-28B GENE POLYMORHISM MAY AFFECT THE NATURAL COURSE OF HEPATITIS B AND DELTA VIRUS INFECTIONS von Bozdayi, A.M, Ozturk, T, Altuntas, S, Karatayli, S.C, Karatayli, E, Inci, C, Cinar, K, Albayrak, R, Ozkan, M, Kendal, Y, Idilman, R, Yurdaydin, C

Volltext

GS-008 - A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study von Yurdaydin, C., Idilman, R., Keskin, O., Kalkan, C., Karakaya, M.F., Caliskan, A., Yurdcu, E., Karatayli, S.C., Bozdayi, M., Koh, C., Heller, T., Glenn, J.

Volltext

THU-161 - The prenylation inhibitor lonafarnib can induce post-treatment viral clearance in patients with chronic delta hepatitis resulting in alt normalization and regression of f... von Yurdaydin, C., Idilman, R., Kalkan, C., Karakaya, M.F., Caliskan, A., Keskin, O., Yurdcu, E., Karatayli, S.C., Bozdayi, M., Koh, C., Heller, T., Glenn, J.

Volltext

FRI-111 - Hepatitis Delta Virus Kinetics under the Prenylation Inhibitor Lonafarnib Suggest HDV-Mediated Suppression of HBV Replication von Yurdaydin, C., Borochov, N., Kalkan, C., DebRoy, S., Karatayli, E., Haynes-Williams, V., Karatayli, S.C., Canini, L., Uprichard, S.L., Bozdayi, A. Mihat, Choong, I., Cory, D., Heller, T., Cotler, S., Idilman, R., Glenn, J.S., Dahari, H.

Volltext

PVI-23 Molecular epidemiology and genotype distribution of hepatitis C virus in Turkey as reflected by phylogenetic analysis of the NS5B region and E1 region von Kabakci, S.G, Çelik, E, Karataylı, S.C

Volltext

PVI-27 Retrospective analysis of mutation patterns in patients with chronic hepatitis B having breakthrough under antiviral treatment von Çelik, E, Kabakçı, S.G, Karataylı, S.C

Volltext

286 POTENTIAL PROTEOMIC BIOMARKERS IN ASSESSING LIVER FIBROSIS USING SELDI-TOF MS von Karatayli, S.C. Ozen, Mizrak, D, Sayki, M, Ozkan, M, Erden, E, Yurdaydin, C, Idilman, R, Bozdayi, A.M

Volltext